This is similar to the observations of Kwak et al. [19] who showed that both pancreatic cancer patients with EGFR mutations exhibited disease stabilization in response to therapy with erlotinib and capecitabine; however, this result does not fall within the same category of dramatic responses seen in NSCLC [9-14]. This evidence concerns the gene EGFR and pancreatic neoplasm.